Log in to save to my catalogue

Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine de...

Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine de...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2070800654

Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

About this item

Full title

Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

Publisher

New York: Springer New York

Journal title

Nature biotechnology, 2018-09, Vol.36 (8), p.758-764

Language

English

Formats

Publication information

Publisher

New York: Springer New York

More information

Scope and Contents

Contents

Therapeutic inhibition of the immunosuppressive IDO1–TDO pathway in tumors is achieved
in vivo
with an enzyme.
Increased tryptophan (Trp) catabolism in the tumor microenvironment (TME) can mediate immune suppression by upregulation of interferon (IFN)-γ-inducible indoleamine 2,3-dioxygenase (IDO1) and/or ectopic expression of the predomina...

Alternative Titles

Full title

Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2070800654

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2070800654

Other Identifiers

ISSN

1087-0156

E-ISSN

1546-1696

DOI

10.1038/nbt.4180

How to access this item